Skip to main content
. 2016 Jan 25;11(4):1074–1081. doi: 10.1021/acschembio.5b00948

Figure 1.

Figure 1

Structures of the FDA-approved INSTIs (RAL, 1; EVG, 2; and DTG, 3) and heterobicyclic compounds of the current series (4). Colors highlight key functional features: metal-chelating triad of heteroatoms (red), halobenzyl rings (blue). The terminal ring of DTG and the corresponding 6-substituents described in the present work shown in green shading.